Raltegravir + Ledipasvir/Sofosbuvir = Unknown or no reaction

Effect on Concentration

Raltegravir
No change
Applies within class?
No
Ledipasvir/Sofosbuvir
No change
Applies within class?
No

Pharmacologic Effects

Raltegravir
Effect
N/A
Applies within class?
No
Ledipasvir/Sofosbuvir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 16-Jul-2018

Summary

Sources

Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. ^

Study Design

The ION-4 study analyzed the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in the HIV/HCV co-infected population. Permitted concomitant ARVs included raltegravir (RAL), efavirenz and rilpivirine, with a NRTI backbone of emtricitabine/tenofovir (FTC/TDF). The primary efficacy endpoint was SVR12.

Study Results

Results showed that 97% of subjects taking RAL + TDF/FTC (n=146) achieved SVR12. No patient had confirmed HIV virologic rebound (HIV RNA of 400 copies/ml or more) and none discontinued study drug due to adverse effects. Additionally, no significant lab abnormalities were observed.

Study Conclusions

The manufacturer for LDV/SOF states that there is no clinically significant interaction with RAL and these agents may be co-administered.

References

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Gane E. Ledipasvir and sofosbuvir for hcv in patients coinfected with hiv-1. New England Journal Of Medicine. 2015; 8: 705-713.